In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
12 authors.
Aishwarya S PawarDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0002-1644-1201 Patrick SomersDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Aleena AlexDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Subin S GeorgeInstitute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0002-3452-0528 Charles AntonyDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0003-3574-4184 Roman VernerDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Sanese K White-BrownCenter for Personalized Diagnostics, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-9521-222X Mohit KheraDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
María Saraí Mendoza-FigueroaDepartment of Biochemistry & Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0002-3959-0904 Kathy Fange LiuDepartment of Biochemistry & Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0001-5943-3888 Jennifer J D MorrissetteCenter for Personalized Diagnostics, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0009-0003-5254-0076 Vikram R ParalkarDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0001-6413-951X Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MRegulation of rRNA transcription in mammalian tissuesR35GM138035 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Vikram R. Paralkar · 2020 to 2026
$3.2MCoregulation of mRNA, tRNA, and rRNA species through RNA modificationsR35GM133721 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI LIU, FANGE · 2019 to 2023
$2.5MThe Role of PHF6 in HSC self-renewal and myeloid expansionR01HL155144 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PARALKAR, VIKRAM R. · 2021 to 2024
$2.2MNCI NIH HHS P30 CA016520NHLBI NIH HHS R01 HL155144NIGMS NIH HHS R35 GM133721NIGMS NIH HHS R35 GM138035
6 · The paper itselfAbstract
Myeloid leukemias are heterogeneous cancers with diverse mutations, sometimes in genes with unclear roles and unknown functional partners. PHF6 and PHIP are two poorly-understood chromatin-binding proteins recurrently mutated in acute myeloid leukemia (AML).
Indexed as
AMLleukemiamyeloidPHF6PHIPstemness
Identifiers
PMID39677666
PMCPMC11642813
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390